| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 05/07/2013 | US8435534 Cancer immunotherapy |
| 05/07/2013 | US8435527 Purification method which prevents denaturation of an antibody |
| 05/07/2013 | US8435525 FGF modulation of in vivo antibody production and humoral immunity |
| 05/07/2013 | US8435523 Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| 05/07/2013 | US8435522 Humanized antibodies against CXCR3 |
| 05/07/2013 | US8435515 Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof |
| 05/07/2013 | US8435513 NOTCH1 receptor antibodies and methods of treatment |
| 05/07/2013 | US8435511 Anti-hepsin antibodies and methods using same |
| 05/07/2013 | US8435510 Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| 05/02/2013 | WO2013063613A2 Methods and compositions related to intracellular neutralization by igg |
| 05/02/2013 | WO2013063536A1 Actriib binding agents and uses thereof |
| 05/02/2013 | WO2013063516A1 Humanized antibodies that recognize alpha-synuclein |
| 05/02/2013 | WO2013063498A1 Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies |
| 05/02/2013 | WO2013063284A1 Antibody formulations and methods |
| 05/02/2013 | WO2013063114A1 Immunobinders directed against tnf |
| 05/02/2013 | WO2013063110A1 Bispecific immunobinders directed against tnf and il-17 |
| 05/02/2013 | WO2013063095A1 Immunobinders directed against sclerostin |
| 05/02/2013 | WO2013062841A1 Removal of virucidal agents in mixed mode chromatography |
| 05/02/2013 | WO2013061594A1 Topk peptides and vaccines including the same |
| 05/02/2013 | WO2013061083A2 Therapeutic agents and uses thereof |
| 05/02/2013 | WO2013061048A1 Pulmonary hypertension |
| 05/02/2013 | WO2013061010A1 Transcription unit and use thereof in (yb2/0) expression vectors |
| 05/02/2013 | WO2013060867A2 Production of heterodimeric proteins |
| 05/02/2013 | WO2013021279A3 Highly galactosylated antibodies |
| 05/02/2013 | WO2013016468A3 Compositions and methods for improving potency and breadth or hiv antibodies |
| 05/02/2013 | WO2012162561A3 Multivalent and monovalent multispecific complexes and their uses |
| 05/02/2013 | WO2012156963A3 Immunoglobulin reduced in thrombogenic agents and preparation thereof |
| 05/02/2013 | US20130111613 Colon disease targets and uses thereof |
| 05/02/2013 | US20130109847 Detection or quantification of desirable target molecules, novel dyes, composite dyes, and oligonucleotides or polynucleotides comprising such dyes |
| 05/02/2013 | US20130109846 Compositions monovalent for cd28 binding and methods of use |
| 05/02/2013 | US20130109845 Fully human influenza m2 specific antibodies |
| 05/02/2013 | US20130109844 ANTI-cMET ANTIBODY |
| 05/02/2013 | US20130109843 Antibodies to human programmed death receptor pd-1 |
| 05/02/2013 | US20130109842 Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23 |
| 05/02/2013 | US20130109841 ANTI-cMET ANTIBODY |
| 05/02/2013 | US20130109840 ANTI-cMET ANTIBODY |
| 05/02/2013 | US20130109838 Method of altering the binding specificity of plasma proteins by oxidation-reduction |
| 05/02/2013 | US20130109645 Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| 05/02/2013 | US20130109593 Expression of monoclonal antibodies in ciliate host cells |
| 05/02/2013 | US20130109587 Usp2a peptides and antibodies |
| 05/02/2013 | US20130108690 Anti-apoptotic protein antibodies |
| 05/02/2013 | US20130108660 Anti-trypanosome therapeutic and diagnostic applications |
| 05/02/2013 | US20130108653 Bivalent molecules for hiv entry inhibition |
| 05/02/2013 | US20130108651 Antibodies to human programmed death receptor pd-1 |
| 05/02/2013 | US20130108650 Actriib binding agents and uses thereof |
| 05/02/2013 | US20130108644 Inhibition of AXL Signaling in Anti-Metastatic Therapy |
| 05/02/2013 | US20130108642 IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH |
| 05/02/2013 | US20130108641 Anti-gitr antibodies |
| 05/02/2013 | US20130108640 Antikine antibodies that bind to multiple cc chemokines |
| 05/02/2013 | US20130108639 Pharmaceutical composition for preventing or treating cancer |
| 05/02/2013 | US20130108638 Antagonist antibodies against ephb3 |
| 05/02/2013 | US20130108636 High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
| 05/02/2013 | US20130108629 Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof |
| 05/02/2013 | US20130108627 Humanized pcrv antibody having anti-pseudomonal activity |
| 05/02/2013 | US20130108624 Cryptic glycan markers and applications thereof |
| 05/02/2013 | US20130108623 Antibodies with Enhanced or Suppressed Effector Function |
| 05/02/2013 | US20130108622 Disulfide stabilized antibodies and fragments thereof |
| 05/02/2013 | US20130108621 ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND THE USE THEREOF IN IMMUNE THERAPIES |
| 05/02/2013 | US20130108618 METHODS AND COMPOSITIONS RELATED TO INTRACELLULAR NEUTRALIZATION BY IgG |
| 05/02/2013 | US20130108547 Recombinantly Produced Antibodies Targeting ErbB Signaling Molecules and Methods of Use Thereof for the Diagnosis and Treatment of Disease |
| 05/02/2013 | US20130108546 Humanized Antibodies That Recognize Alpha-Synuclein |
| 05/02/2013 | DE112011102396T5 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Diabetes und metabolischen Störungen A pharmaceutical combination composition and methods for the treatment of diabetes and metabolic disorders |
| 05/02/2013 | CA2853734A1 Methods and compositions related to intracellular neutralization by igg |
| 05/02/2013 | CA2853719A1 Humanized antibodies to inkt |
| 05/02/2013 | CA2853669A1 Therapeutic agents and uses thereof |
| 05/02/2013 | CA2853637A1 Monoclonal antibodies and methods of use |
| 05/02/2013 | CA2853531A1 Humanized antibodies that recognize alpha-synuclein |
| 05/02/2013 | CA2853412A1 Tdp-43 specific binding molecules |
| 05/02/2013 | CA2853357A1 Immunobinders directed against tnf |
| 05/02/2013 | CA2853258A1 Immunobinders directed against sclerostin |
| 05/02/2013 | CA2853114A1 Bispecific immunobinders directed against tnf and il-17 |
| 05/02/2013 | CA2853112A1 Antibody formulations and methods |
| 05/02/2013 | CA2852633A1 Topk peptides and vaccines including the same |
| 05/02/2013 | CA2852629A1 Usp2a peptides and antibodies |
| 05/02/2013 | CA2851545A1 Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies |
| 05/02/2013 | CA2850328A1 Transcription unit and use thereof in (yb2/0) expression vectors |
| 05/01/2013 | EP2586798A2 B-cell reduction using CD37-specific and CD20-specific binding molecules |
| 05/01/2013 | EP2586797A2 Humanized anti-amyloid beta antibodies |
| 05/01/2013 | EP2586796A1 Compositions and methods for use for antibodies against sclerostin |
| 05/01/2013 | EP2586795A2 Use of anti-amyloid beta antibody in ocular diseases |
| 05/01/2013 | EP2585828A2 Methods of treating patients with immune-related diseases |
| 05/01/2013 | EP2585607A2 Dual variable domain immunoglobulins and uses thereof |
| 05/01/2013 | EP2585488A2 Novel biomarkers of liver cancer |
| 05/01/2013 | EP2585110A1 Antibodies to the c3d fragment of complement component 3 |
| 05/01/2013 | EP2585107A1 Homodimeric protein constructs |
| 05/01/2013 | EP2585045A2 Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
| 05/01/2013 | CN1662556B Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| 05/01/2013 | CN103080302A Medium composition for culturing self-activated lymphocytes and method for culturing self-activated lymphocytes using same |
| 05/01/2013 | CN103080136A Anti-Axl antibodies and methods of use |
| 05/01/2013 | CN103080135A Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| 05/01/2013 | CN103080134A Antibodies for epidermal growth factor receptor 3 (HER3) |
| 05/01/2013 | CN103080133A Anti-VEGFR-3 antibody compositions |
| 05/01/2013 | CN103080132A Antibodies against IL-18R1 and uses thereof |
| 05/01/2013 | CN103080131A Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies |
| 05/01/2013 | CN103080130A Method for preparing antibodies having improved properties |
| 05/01/2013 | CN103080129A Plasma-derived immunoglobulin for use in the treatment and prevention of immune reconstitution inflammatory syndrome (IRIS) |
| 05/01/2013 | CN103079644A Anti-TIM-3 antibody |
| 05/01/2013 | CN103079594A Uses and compositions for treatment of hidradenitis suppurativa (HS) |
| 05/01/2013 | CN103074316A Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| 05/01/2013 | CN103074303A Hybridoma cell strain generating anti-human NGAL specific monoclonal antibody, monoclonal antibody generated by same and application |